SOURCE: Market Pulse

January 07, 2010 08:30 ET

Market Pulse Breaking News Alert for Thursday, January 7, 2010: ARYC -- Major News Media Missed the Mark! There Is a NEW Pre-Symptomatic Screening Test for Ovarian Cancer From Arrayit Corporation!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Market Pulse.

ATLANTA, GA--(Marketwire - January 7, 2010) - Market Pulse News Alert for this AM, Stocks to Watch are: Arrayit Corporation (OTCBB: ARYC), VIVUS Inc. (NASDAQ: VVUS), China Direct Industries Inc. (NASDAQ: CDII) and Bergio International Inc. (OTCBB: BRGO).

Investors need to be watching Arrayit Corporation (OTCBB: ARYC) this AM! Arrayit Corporation is engaged in the development, manufacture, and marketing of life science technologies and integrated systems for the analysis of genetic variation, biological function, and diagnostics. Arrayit offers a product line of approximately 650 tools to 2,500 laboratories worldwide. The company's products include microarrayers, microarray scanners, DNA and protein microarrays, microarray printing, microarray substrates and slides, microarray instruments, amplification and labeling, purification kits, microarray hardware, buffers and solutions, microarray cleanrooms, books and software, CGH microarrays, and microarray platforms. Arrayit's worldwide business position leverages the company's widely used patented microarray manufacturing platform and revolutionary VIP™ genotyping technology. Nearly every major research center in the world uses Arrayit products including research laboratories, pharmaceutical companies, universities, biotechnology companies, hospitals, government agencies, and nonprofit research organizations. The company is also involved in the import, export, and distribution of industrial and food grade chemicals for plastics, fertilizers, and green energy applications. It has research collaboration with The Parkinson's Institute of Sunnyvale to discover biomarkers for Parkinson's disease. ARYC recently announced that it is developing a microarray-based diagnostic test to detect the H1N1 swine flu virus. The 2009 swine flu outbreak has raised concerns at the CDC and the World Health Organization (WHO). The CDC and WHO believe that the current outbreak poses a pandemic risk because the H1N1 flu virus contains genetic elements from both the swine and human influenza viruses, allowing direct human-to-human transmission without the need for agricultural contact. Arrayit is an exciting and innovative public company that strives to increase shareholder equity by inventing, developing, manufacturing and supplying sophisticated life sciences products and services to an extensive customer base spanning 50 countries. Arrayit is a leader in the field of molecular diagnostics with patented technology that allows the screening and monitoring of up to 80,000 patient samples on a single microscope slide, rather than testing one patient per slide as is currently practiced. Their corporate philosophy is embodied by a highly skilled, multidisciplinary team of investors, business professionals, scientists, engineers and executive and support staff who place shareholder value, product quality, customer service and price competitiveness as their highest priorities. Arrayit empowers decisive strategic advantage and large return on investment for their customers in the research, pharmaceutical, diagnostic, and health care markets! ARYC just had excellent news out in a press release before today's opening bell announcing a breakthrough in ovarian cancer screening utilizing a microarray-based diagnostic test that will detect whether a patient is pre-symptomatic for this silent killer! The company also said this screening test for ovarian cancer will be available soon! This could be big news for investors!

On December 9, 2009, Arrayit Corporation (OTCBB: ARYC), a leading manufacturer of products and services for disease prevention, treatment and cure, announced a breakthrough in ovarian cancer screening utilizing a microarray-based diagnostic test that will detect whether a patient is pre-symptomatic for this silent killer.

In a report by NBC's Dr. Robert Bezell on Tuesday, January 5th, it was reported that although testing continues, there is no effective screening test currently available to detect the pre-symptomatic presence of ovarian cancer. The report missed the mark, which indicates that press information distributed by Arrayit on December 17th, somehow fell through the cracks. The fact is, Arrayit's advanced screening test, OvaDxTM, will be available very soon.

Researchers at a major cancer research institute have worked for six years to identify more than 100 biomarkers unique to ovarian cancer. The proteomic markers were finally identified using a novel and patented microarray platform created by Arrayit. A noninvasive screening test can be performed via a simple blood test that can be conducted during annual physical exams. The test will soon be submitted to the FDA for approval, and since it is an in vitro diagnostic multivariate index assay, prompt approval is anticipated.

According to the American Cancer Society, more than 21,500 women will be diagnosed with Ovarian Cancer this year, and 14,000 will die. Up until now, screening tests could only detect the 'Silent Killer' when the disease is symptomatic, meaning the disease has progressed to stage 3 or 4. Unfortunately at this late stage of detection the cancer most certainly has metastasized and spread beyond the ovary, which proves fatal for 75% of women diagnosed.

Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. Clinicians state that the primary reasons for such a high fatality rate are that there are no discernable early symptoms, and there has not been an effective early detection test available. The American Cancer Society estimates that 90% of woman diagnosed with ovarian cancer could survive with early detection. Currently only 20% of women diagnosed are in the early stages.

The early detection of ovarian cancer holds tremendous potential to profoundly impact the quality of life of ovarian cancer victims and shift costs from treatment to detection ensuring survivability for a larger population. Upon FDA approval, OvaDxTM will be marketed and sold by Arrayit Corporation's subsidiary, Arrayit Diagnostics (Ovarian), Inc., in Houston, Texas under a licensing agreement.

About Arrayit

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. Arrayit now offers over 650 products to a customer base of more than 10,000 clinics and research facilities, and more than 5,000 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit for more information.

Stocks in the news and acting well as of late include: VIVUS Inc. (NASDAQ: VVUS), China Direct Industries Inc. (NASDAQ: CDII) and Bergio International Inc. (OTCBB: BRGO).

Information contained herein is the opinion of ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated, in connection with its profile of Arrayit Corporation, one hundred thousand shares of Arrayit Corporation's common stock by a third party shareholder. Additionally, MP bought for its own account in the open market, forty thousand shares of Arrayit Corporation's shares for a total purchase price of twenty three thousand eight hundred twenty dollars. To date, MP has sold seventy thousand shares of stock in Arrayit Corporation for proceeds totaling sixty five thousand seven hundred twenty three dollars. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. and Market Pulse Breaking News Alert are owned by Market Pulse LLC.

Contact Information